Yeleswaram Krishnaswamy sold $2.5M of RAPP
Yeleswaram Krishnaswamy (Chief Development Officer) sold 50,160 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $50.47 ($50.00–$51.06, $2.53M total) across 3 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction provides fresh data on insider sentiment, useful for short‑term positioning.
Market read
Primary insider sale; modest trading relevance for RAPP.
What to watch
The 10b5‑1 plan pre‑arranged execution reduces the informational value of the sale.
Background
Form 4 filings disclose insider trades; a $2.5M sale by a senior officer is noteworthy for traders.
Ticker impact
Chief Development Officer sold 50,160 shares for $2.53M via a 10b5‑1 plan.
Possible modest downside of 2‑4% over the next few days.
The sale size is material for a mid‑cap biotech and executed under a pre‑arranged plan, suggesting a neutral to slightly bearish signal.
Market effects
May prompt scrutiny of other biotech insider transactions.
Limited to US biotech investors.
Low global impact.
Counterpoint
Insider may be diversifying; sale does not necessarily reflect company outlook.
Key entities
- companyRapport Therapeutics, Inc.
Biotech firm developing therapeutic candidates.
- personYeleswaram Krishnaswamy
Chief Development Officer of Rapport Therapeutics.